Asunto(s)
Certolizumab Pegol , Desensibilización Inmunológica , Hipersensibilidad a las Drogas , Humanos , Certolizumab Pegol/efectos adversos , Certolizumab Pegol/uso terapéutico , Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/inmunología , Inyecciones Subcutáneas , Femenino , Masculino , Persona de Mediana EdadAsunto(s)
Humanos , Femenino , Anciano , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Antivirales/efectos adversos , Infecciones por Coronavirus/tratamiento farmacológico , Hipersensibilidad Tardía/diagnóstico , Hipersensibilidad Tardía/etiología , Pruebas CutáneasAsunto(s)
Hipersensibilidad a las Drogas , Hipersensibilidad Tardía , Hipersensibilidad Inmediata , Humanos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Pruebas Cutáneas , Alanina/efectos adversos , Hipersensibilidad Tardía/diagnóstico , Hipersensibilidad Tardía/inducido químicamenteRESUMEN
Summary: Objectives. Evaluate the changes in quality of life of patients with allergic rhinoconjunctivitis (AR), with or without asthma, after one-year treatment with allergen immunotherapy. Methods. This was an observational prospective multicenter study. RQLQ questionnaire and VAS scale to assess treatment satisfaction were used. Impact on AR and asthma was also analyzed. Any adverse reaction was recorded. Results. 127 patients were recruited. Mean values in RQLQ decreased from 2.61 to 1.34 points, reflecting a statistically and clinically significant improvement (p minor 0.01). The percentage of asthmatic patients decreased significantly (p minor 0.01). Mean value of patients' satisfaction was 7.24 (SD = 1.90). Only 11 patients presented systemic reactions (9.17%), none of them serious. Conclusions. One-year AIT treatment significantly increases QoL in patients with AR. Moreover, high patients' satisfaction values were reported, together with an adequate safety profile.